NeuroOne Q3 Revenue Jumps 105 Percent
NeuroOne Medical Technologies(NASDAQ:NMTC) reported fiscal third quarter 2025 earnings on August 14, 2025, with product revenue up 105% year-over-year to $1.7 million and product gross margins rising to 53.9% from 34.1% in the third quarter of fiscal year 2024. Notable progress included new clinical milestones for its OneRF ablation system, first commercial activity in drug delivery, a strengthened balance sheet following an $8.2 million capital raise in April 2025, and a reiteration of raised full-year guidance for product revenue of $8 million to $10 million, and gross margin of 50% to 53% for fiscal year 2025. For reference, the fiscal year ends September 30, 2025.
Operating expenses decreased 9% year-over-year to $2.8 million, while net loss per share (GAAP) improved to $0.03 from $0.10 year-over-year due to higher sales and disciplined spending. Licensing revenue, derived exclusively from Zimmer Biomet, reached $3 million for the first nine months of fiscal year 2025, up from zero in the same period of fiscal year 2024.
The company’s improved margins, reduced losses, and debt-free status reflect effective cost controls and provide a longer financial runway, supported by contractual minimum orders from Zimmer Biomet.
Source Fool.com
